INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0

48 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2020.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 35 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $439M of principal .
Largest 10 bondholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($57.8M of principal), Silver Point Capital L.P. ($57.4M of principal), DeepCurrents Investment Group LLC ($35.9M of principal), UBS ASSET MANAGEMENT AMERICAS INC ($35M of principal), WOLVERINE ASSET MANAGEMENT LLC ($33.1M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($27.4M of principal), Whitebox Advisors LLC ($23.2M of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($23M of principal), OAKTREE CAPITAL MANAGEMENT LP ($19.4M of principal), and Kohlberg Kravis Roberts & Co. L.P. ($17.5M of principal).
This table shows the top 35 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.